Last reviewed · How we verify
Uncomplicated Urinary Tract Infections
Approved treatments
- Blujepa · Glaxosmithkline
Blujepa works by inhibiting bacterial DNA polymerase, preventing the replication of bacterial DNA and ultimately leading to bacterial cell death. - Test formulation (Treatment A) · Pfizer
- Various · Pfizer
Clinical guidelines
- FDA label — 1L
Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. - FDA label — 1L
Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections due to specified bacteria.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Uncomplicated Urinary Tract Infections patent landscape — cliff calendar, originator estates, attackable patents
- Uncomplicated Urinary Tract Infections treatment landscape brief
- Uncomplicated Urinary Tract Infections treatment updates RSS
Frequently asked questions about Uncomplicated Urinary Tract Infections
What drugs treat Uncomplicated Urinary Tract Infections?
Tracked treatments include Blujepa, Test formulation (Treatment A), Various.
What is the treatment for Uncomplicated Urinary Tract Infections?
Standard treatment for Uncomplicated Urinary Tract Infections includes Blujepa, Test formulation (Treatment A), Various. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Uncomplicated Urinary Tract Infections?
FDA label publishes guidelines for Uncomplicated Urinary Tract Infections. 2 guideline references tracked.
Related
- Treatment landscape: Uncomplicated Urinary Tract Infections patent cliff · Uncomplicated Urinary Tract Infections CI report
- Treatment: Blujepa · Glaxosmithkline
- Treatment: Test formulation (Treatment A) · Pfizer
- Treatment: Various · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing